Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
VYNE 
Vyne Therapeutics Inc (VYNE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: VYNE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $6.38
1 Year Target Price $6.38
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -5.87% | Avg. Invested days 22 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 23.66M USD | Price to earnings Ratio - | 1Y Target Price 6.38 |
Price to earnings Ratio - | 1Y Target Price 6.38 | ||
Volume (30-day avg) 4 | Beta 1.58 | 52 Weeks Range 0.85 - 4.30 | Updated Date 06/30/2025 |
52 Weeks Range 0.85 - 4.30 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.98 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -4552.97% |
Management Effectiveness
Return on Assets (TTM) -38.37% | Return on Equity (TTM) -66.15% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -26544854 | Price to Sales(TTM) 39.11 |
Enterprise Value -26544854 | Price to Sales(TTM) 39.11 | ||
Enterprise Value to Revenue 10.04 | Enterprise Value to EBITDA 1.84 | Shares Outstanding 16664900 | Shares Floating 13554223 |
Shares Outstanding 16664900 | Shares Floating 13554223 | ||
Percent Insiders 8.34 | Percent Institutions 47.62 |
Analyst Ratings
Rating 2 | Target Price 6.38 | Buy 1 | Strong Buy 3 |
Buy 1 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Vyne Therapeutics Inc
Company Overview
History and Background
Vyne Therapeutics Inc., formerly Menlo Therapeutics Inc., focuses on developing and commercializing innovative therapeutics for dermatology. Founded in 2011 and changing its name to Vyne in 2020, the company has pivoted its focus over time, seeking to address unmet needs in skin health.
Core Business Areas
- Dermatology Therapeutics: Focuses on the development and commercialization of prescription dermatology products for a range of skin conditions.
Leadership and Structure
The company has a management team led by the CEO and supported by various department heads. Its organizational structure comprises research & development, commercial operations, and administrative functions.
Top Products and Market Share
Key Offerings
- AMZEEQ (minocycline) topical foam, 4%: AMZEEQ is a topical minocycline foam for the treatment of moderate to severe acne vulgaris in adults and children 9 years of age and older. Competitors include topical retinoids, benzoyl peroxide products, and other topical and oral antibiotics. Market share information unavailable.
- ZILXI (minocycline) topical foam, 1.5%: ZILXI is a topical minocycline foam indicated for the treatment of inflammatory lesions of rosacea in adults. Competitors include topical metronidazole, azelaic acid, and other topical antibiotics. Market share information unavailable.
Market Dynamics
Industry Overview
The dermatology market is characterized by a growing demand for effective treatments for various skin conditions, driven by an aging population, increasing awareness of skin health, and advancements in dermatological research.
Positioning
Vyne Therapeutics aims to differentiate itself through innovative topical formulations targeting specific skin conditions. Its competitive advantage lies in its proprietary foam technology.
Total Addressable Market (TAM)
The global dermatology market is estimated to be in the tens of billions of dollars. Vyne Therapeutics targets specific segments within this large market, focusing on acne and rosacea treatments. Their success depends on capturing a portion of this TAM through effective products and marketing.
Upturn SWOT Analysis
Strengths
- Proprietary foam technology
- FDA-approved products
- Focus on underserved dermatology segments
Weaknesses
- Limited product portfolio
- Reliance on sales of a few key products
- History of financial losses
- High operating expenses
Opportunities
- Expansion of product pipeline
- Geographic expansion
- Partnerships and collaborations
- Further develop and commercialize new applications of the foam technology
Threats
- Competition from established pharmaceutical companies
- Pricing pressures
- Generic erosion
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- LEO
- GALD
- DERM
Competitive Landscape
Vyne Therapeutics faces competition from larger, more established pharmaceutical companies with broader product portfolios and greater resources. Its advantage lies in niche dermatology segments.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been inconsistent due to strategic changes and product development cycles.
Future Projections: Future growth projections depend on the success of existing products and the development of new products. Analyst estimates are generally available from financial data providers.
Recent Initiatives: Recent initiatives include focusing on core dermatology products and seeking partnerships to expand their reach.
Summary
Vyne Therapeutics is a small pharmaceutical company focused on dermatology. Its strengths lie in its proprietary technology and approved products, but it faces challenges related to competition and limited resources. The company needs to successfully commercialize its current products and develop new ones to achieve sustainable growth. Investor should look out for sales growth and profitability signals.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Financial news sources
- Industry reports
- SEC.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimates and may not be precise. Consult with a financial professional before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vyne Therapeutics Inc
Exchange NASDAQ | Headquaters Bridgewater, NJ, United States | ||
IPO Launch date 2018-01-25 | CEO, President & Director Mr. David T. Domzalski | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://vynetherapeutics.com |
Full time employees 13 | Website https://vynetherapeutics.com | ||
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.